Of note, 2 patients in the no-PPH group were diagnosed with complement-mediated TMA related to underlying disease (IgA and systemic lupus erythematosus) but were counted toward the p-aHUS cohort and treated with CIT (Supplementary Table S1). The gene discussed is CD79A; the disease is pulmonary arterial hypertension.